Edition:
United States

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

24.92EUR
23 May 2018
Change (% chg)

-- (--)
Prev Close
€24.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
48,088
52-wk High
€56.48
52-wk Low
€22.30

Select another date:

Thu, May 17 2018

BRIEF-Celyad Announces Pricing Of 47.3 Million Dollars Global Offering

* 1,276,087 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF US AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE OF EUR 22.29PER SHARE

BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update

* GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT

BRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link Trials

* CELYAD SUCCESSFULLY ADMINISTERS CYAD-01 IN FIRST PATIENTS IN SHRINK AND LINK TRIALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient

* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT

BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting

* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018

Select another date: